SHP2抑制使多种致癌基因成瘾的实体瘤对靶向治疗再治疗敏感
PF-07284892是一种变构SHP2抑制剂,旨在与多种致癌驱动因子抑制剂联用时克服旁路信号介导的耐药。在首次人体试验的首个剂量水平,既往靶向治疗耐药的ALK融合阳性肺癌、BRAFV600E突变结直肠癌、KRASG12D突变卵巢癌和ROS1融合阳性胰腺癌患者接受PF-07284892治疗,单药进展后加用既往失败的靶向治疗,联合治疗带来快速肿瘤和ctDNA缓解并延长总体临床获益持续时间。
要点
- PF-07284892联合既往失败的靶向治疗可克服旁路信号介导的耐药。
- 联合治疗在单药均无活性情况下带来快速肿瘤和ctDNA缓解。
- 联合治疗延长了总体临床获益持续时间。
核心结论
- PF-07284892联合靶向治疗在两种成分单药均无活性的临床情境中克服了旁路信号介导的耐药。
- 这为SHP2抑制剂克服多种靶向治疗耐药提供了概念验证,并为临床开发早期加速测试新药联合提供了范式。
研究设计与样本
- PF-07284892(ARRY-558)是一种变构SHP2抑制剂,设计用于与多种致癌驱动因子抑制剂联用时克服旁路信号介导的耐药。
- 在首次人体临床试验的首个剂量水平,既往靶向治疗耐药的ALK融合阳性肺癌、BRAFV600E突变结直肠癌、KRASG12D突变卵巢癌和ROS1融合阳性胰腺癌患者接受PF-07284892治疗。
- PF-07284892单药进展后,新颖研究设计允许加用既往失败的致癌基因导向靶向治疗。
主要发现
- 联合治疗带来快速肿瘤和循环肿瘤DNA(ctDNA)缓解。
- 联合治疗延长了总体临床获益持续时间。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Rationally targeted therapies have transformed cancer treatment, but many patients develop resistance through bypass signaling pathway activation. PF-07284892 (ARRY-558) is an allosteric SHP2 inhibitor designed to overcome bypass-signaling-mediated resistance when combined with inhibitors of various oncogenic drivers. Activity in this setting was confirmed in diverse tumor models. Patients with ALK fusion-positive lung cancer, BRAFV600E-mutant colorectal cancer, KRASG12D-mutant ovarian cancer, and ROS1 fusion-positive pancreatic cancer who previously developed targeted therapy resistance were treated with PF-07284892 on the first dose level of a first-in-human clinical trial. After progression on PF-07284892 monotherapy, a novel study design allowed the addition of oncogene-directed targeted therapy that had previously failed. Combination therapy led to rapid tumor and circulating tumor DNA (ctDNA) responses and extended the duration of overall clinical benefit. SIGNIFICANCE: PF-07284892-targeted therapy combinations overcame bypass-signaling-mediated resistance in a clinical setting in which neither component was active on its own. This provides proof of concept of the utility of SHP2 inhibitors in overcoming resistance to diverse targeted therapies and provides a paradigm for accelerated testing of novel drug combinations early in clinical development. See related commentary by Hernando-Calvo and Garralda, p. 1762. This article is highlighted in the In This Issue feature, p. 1749.
引用
- Drilon A, Sharma MR, Johnson ML, et al. SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy. Cancer Discov. 2023. PMID: 37269335. doi:10.1158/2159-8290.CD-23-0361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。